CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer
Mark L. McCleland, Kathryn Mesh, Edward G. Lorenzana et al. · Journal of Clinical Investigation · 2016
Colon tumors arise in a stepwise fashion from either discrete genetic perturbations or epigenetic dysregulation. To uncover the key epigenetic regulators that drive colon cancer growth, we used a CRISPR loss-of-function screen and identified a number of essential genes, including the bromodomain and extraterminal (BET) protein BRD4. We found that BRD4 is critical for colon cancer proliferation, and its knockdown led to differentiation effects in vivo. JQ1, a BET inhibitor, preferentially reduced growth in a subset of epigenetically dysregulated colon cancers characterized by the CpG island methylator phenotype (CIMP). Integrated transcriptomic and genomic analyses defined a distinct superenhancer in CIMP+ colon cancers that regulates cMYC transcription. We found that the long noncoding RNA colon cancer-associated transcript 1 (CCAT1) is transcribed from this superenhancer and is exquisitely sensitive to BET inhibition. Concordantly, cMYC transcription and cell growth were tightly correlated with the presence of CCAT1 RNA in a variety of tumor types. Taken together, we propose that CCAT1 is a clinically tractable biomarker for identifying patients who are likely to benefit from BET inhibitors.
Cited by 219 works. doi:10.1172/jci83265
Authors
- Mark L. McCleland
- Kathryn Mesh
- Edward G. Lorenzana
- Vivek S. Chopra
- Ehud Segal
- Colin K. Watanabe
- Benjamin Haley
- Oleg Mayba
- Murat Yaylaoglu
- Florian Gnad
- Ron Firestein
References
- A genetic model for colorectal tumorigenesis
- Multiplex Genome Engineering Using CRISPR/Cas Systems
- RNA-Guided Human Genome Engineering via Cas9
- Identification of a Chromosome 18q Gene that Is Altered in Colorectal Cancers
- Cancer Genome Landscapes
- APC mutations occur early during colorectal tumorigenesis
- Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
- RNA-programmed genome editing in human cells
- CpG island methylator phenotype in colorectal cancer
- Gene Silencing in Cancer in Association with Promoter Hypermethylation